EuroBiotech: More Articles of Note


> Millendo Therapeutics bought France’s Alizé Pharma. Statement 

> Summit Therapeutics offloaded the Latin American rights to its Clostridium difficile infection drug. Statement

> The EMA’s drug review committee recommended the approval of TiGenix and Takeda’s allogeneic stem cell therapy. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Active Biotech warned it must sell a property or otherwise raise money before the end of February, otherwise it “will not have funding for the coming twelve-month period.” Statement

> The FDA awarded qualified infectious disease product status to Basilea Pharmaceutica’s ceftobiprole. Release 

> Ablynx posted data from a Japanese ethno-bridging study of caplacizumab. Statement 

> BiomX bought RondinX to expand its microbiome discovery and development capabilities. Release

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.